TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01133990
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI will be administered as IV infusion on Days 1 and 15 of each cycle, and 5-FU at 400 mg/m\^2 as an IV bolus injection followed by a total of 2400 mg/m2 by CIV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump. The 5-FU IV bolus (400 mg/m\^2) and CIV infusion (2400 mg/m\^2) over 46 hours is repeated on Days 15 and 16 of each cycle.
Study: NCT00649155
Drug: Cipro® XR Tablets (500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg, single dose fasting
Study: NCT00005866
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: arm 2: 60 mg/kg every 24 hrs for 2 doses, IV over 2 hrs, days -5 and -4
Study: NCT00005866
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GVHD: 15 mg/m2 day 1, 10 mg/m2 day 3, 6 and 11 by IV
Study: NCT04575597
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
Study: NCT01653132
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile, preservative free 0.9% saline, 1 ml, was used as placebo, and injected into the parotid (0.2 ml each) and submandibular (0.3ml each) glands .
Study: NCT00976118
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo to masitinib
Study: NCT00041587
Drug: IL13-PE38QQR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04607928
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparing the effect of pirfenidone in avoiding establishing or progression of fibrosis induced after COVID19 infection
Study: NCT03255070
Drug: ARX788
Approvals — FDA: no, EMA: no, PMDA: no
Description: An antibody drug conjugate
Study: NCT00539201
Drug: GSK706769
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03131466
Drug: Nerve block
Normalized name: Nerve Block Tray 22g
Approvals — FDA: no, EMA: no, PMDA: no
Description: The radiofrequency generator will be set at the sensory stimulating mode, and the lowest frequency of 0.2 V will be used for 360s-sham PRF treatment, after which 1.4 mL of a mixture of 2 mg of dexamethasone sodium phosphate and 1 mL of 1% plain lidocaine will be slowly injected through the radiofrequency treatment cannula needle. Before the needle being removed, 0.5 mL of normal saline will be injected.
Study: NCT02866370
Drug: Pegylated Liposomal Doxorubicin (PLD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovarian Cancer Patients Pegylated Liposomal Doxorubicin (PLD) (40mg/m2) IV every 28 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2.
Study: NCT02866370
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endometrial Cancer Patients Doxorubicin IV 60mg/m2 every 21 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2.
Study: NCT02093468
Drug: MST-188
Normalized name: MST 600
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03671590
Drug: TG-1701
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily dose
Study: NCT04678206
Drug: BLU-5937
Normalized name: Blu-Kote
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of BLU-5937 Tablets
Study: NCT04678206
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of matching placebo for BLU-5937 Tablets
Study: NCT00126880
Drug: AVX754
Approvals — FDA: no, EMA: no, PMDA: no
Description: apricitabine, 600mg BID or 800mg BID
Study: NCT02726308
Drug: 10 ml/kg Ringer's lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-operative 10 ml/kg Ringer's lactate solution .
Study: NCT02726308
Drug: 30 ml/kg Ringer's lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-operative 30 ml/kg Ringer's lactate solution .
Study: NCT03207438
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03252600
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01367080
Drug: DWETR10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline hydrochloride 10mg(DWETR10) single dose
Study: NCT01367080
Drug: DWETR25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline hydrochloride 25mg(DWETR25) single dose
Study: NCT01820624
Drug: tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01944839
Drug: E10030
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02646137
Drug: Transarterial chemoembolization (TACE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE exploits the preferential hepatic arterial supply of liver tumors for targeted delivery of chemotherapeutic agents followed by embolization or reduction in arterial flow using various types of particles
Study: NCT03744091
Drug: P1
Normalized name: P1E1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg or 20 mg of THC:THCa
Study: NCT00924170
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days 1-3:~Patients 1-7, 10 -14, and \>18:250 mg/m\^2/day Patients 8 - 9:300 mg/m\^2/day Patients 15-17:200 mg/m\^2/day
Study: NCT02025556
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously Administered Placebo (Vehicle) Monthly x 3
Study: NCT02620163
Drug: YH22162 40/5/12.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02620163
Drug: YH22162 80/5/25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02620163
Drug: YH22162 40/5/12.5 mg placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02620163
Drug: YH22162 80/5/25 mg placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00394992
Drug: oxaliplatin+capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
Study: NCT02282826
Drug: GZ402668
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution Route of administration: intravenous
Study: NCT02282826
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution Route of administration: intravenous
Study: NCT02282826
Drug: GZ402668
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study: NCT02282826
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study: NCT00812760
Drug: levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 tablet of 200 mg levodopa plus 50 mg benserazide
Study: NCT04138979
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: First use of chemotherapy after breast cancer
Study: NCT00456144
Drug: Gonadotropin Releasing Hormone Agonist Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given either for 24 months and 6 months
Study: NCT02420782
Drug: ASP6282
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02420782
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01325220
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tid
Study: NCT04531631
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00042029
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02694718
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is available as 50 mg and 500 mg tablets. It will be administered as a 1000mg/m\^2 bid orally on Days 1-14, and at a dose of 825mg/m\^2 bid on Days 22-35 and 43-56.
Study: NCT01551940
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: A local ultrasound-guided bilateral injection of placebo (NaCl 0.9 %) in parotid (0.7 ml/gland) and submandibular (0.3 ml/gland) glands.
Study: NCT04160416
Drug: Capecitabine-Oxaliplatin-Irinotecan Combination
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CAP 1,600 mg/sq.m /day (p.o. day1-10) D1-10; Oxaliplatin (OX): 68 mg/sq.m (d.i.v.) D1; Irinotecan (IRI):135 mg/sq.m (d.i.v.) D1; BEV: 5mg/kg (d.i.v.) D1; CET: 500 mg/sq.m (d.i.v.) D1; Administered every 2 weeks.
Study: NCT00266461
Drug: Daikenchuto Extract Granules (TU-100)
Normalized name: mustard pollen extract 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03458598
Drug: Patient controlled opioid analgesia (PCA)
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in both groups will have PCA dilaudid or morphine prescribed for the post-operative period.
Study: NCT02573701
Drug: Guideline treatment (Risperidone, administered orally)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group
Study: NCT02573701
Drug: Treatment as Usual (any other antipsychotic)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive the Treatment as Usual (atypical antipsychotic) plus Behavioral Intervention: psychosocial treatment assigned by clinician.
Study: NCT00384111
Drug: Zevalin Therapeutic Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin. Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin
Study: NCT00384111
Drug: R-CVP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard R-CVP
Study: NCT03657966
Drug: Standard of Care Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: either carboplatin and gemcitabine or carboplatin and paclitaxel followed by DCVAC/OvCa
Study: NCT00995488
Drug: ABI-007 (Abraxane®)
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABI-007 is a novel albumin-bound paclitaxel combining a protein with a chemotherapeutic agent in the particle form.
Study: NCT01501084
Drug: Normal saline .2cc subcutaneous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile saline injection
Study: NCT03419975
Drug: TJO-002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrate the drugs for clinical trial one drop once daily at the same time (9 p.m. ± 1 hour) for a study eye
Study: NCT05958693
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine will be administered for 3 days according to body weight (Days 0 and 8 hours after, 1 and 2). Dosage depending on body weight or age if weight cannot be determined.~Dosage: 1 tablet contains 20 mg artemether and 120 mg lumefantrine Dosage per weight: 1 tablet (5 to \<16kg); 2 tablets (15 to \<25kg); 3 tablets (25 to \<35kg), 4 tablets for \>35 kg) Dosage per age, if weight cannot be determined: 1 tablet (6 months old to 3 years old); 2 tablets (4 to 8 years old); 3 tablets (9-13 years old), 4 tablets (\>13 years old)
Study: NCT03345953
Drug: BP 1.4979
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double blind versus placebo
Study: NCT03345953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double blind versus placebo
Study: NCT00684216
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg, BID, PO, QD until progression of disease
Study: NCT01289990
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 10773 low dose
Study: NCT01289990
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 10773 high dose
Study: NCT01289990
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching Sitagliptin
Study: NCT01181401
Drug: TPF induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 d 1 Cis-platinum 75 mg/m2 d 1 5-FU 750 mg/m2/d c.i. d 1-4 Cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
Study: NCT01181401
Drug: TPF experimental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 40 mg/m2 d 1+8 Cis-platinum 40 mg/m2 d 1+8 5-FU 1500 mg/m2/24h c.i. d 1+8 every 21 day for 3 cycles 2. Antibody therapy with: cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
Study: NCT03945175
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the two-week, placebo lead-in, all patients will receive 12.5mg of placebo at Visit 1 and Visit 2.
Study: NCT00168987
Drug: oral nutritional supplement rich in eicosapentanoic acid
Normalized name: docosahexaenoate / eicosapentaenoate / omega-3 acid ethyl esters (USP) Oral Capsule [Ocean Blue Nutritionals Omega-3 1450]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04493125
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01969539
Drug: Combivent Respimat via tee adapter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via tee adapter
Study: NCT01969539
Drug: Combivent Respimat via ventilator adapter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via ventilator adapter
Study: NCT04022161
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm description
Study: NCT02547883
Drug: Cessation of statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention evaluated is the cessation of statin
Study: NCT01649245
Drug: Reiferon retard
Normalized name: Uniferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible subjects will be treated with Reiferon Retard® 160 µg weekly by subcutaneous injection for 48 weeks, together with weight-based oral ribavirin (1200 mg/day if body weight is \>75 kg and 1000 mg/day if body weight is ≤ 75 kg) in divided doses.
Study: NCT01514370
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received placebo matched to curcumin orally twice a day for 24 months.
Study: NCT00928135
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7% hypertonic saline solution for aerosol; Dosage: 5 ml twice a day (BID)
Study: NCT00624702
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01426789
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to secukinumab I.V.
Study: NCT02200614
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo 2 tablets twice daily with food.
Study: NCT04616742
Drug: [14C]SHR6390
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive single dose of orally \[14C\]SHR6390 on Day 1.
Study: NCT01739855
Drug: Calciferol, calcium carbonate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00278408
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00278408
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02456480
Drug: CLS001
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical gel
Study: NCT02456480
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical gel
Study: NCT02284672
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01307020
Drug: Dexketoprofen Trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen Trometamol low dose, oral film-coated table, once
Study: NCT01307020
Drug: Dexketoprofen Trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen Trometamol high dose, oral film-coated table, once
Study: NCT01307020
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 400 mg, oral film-coated table, once
Study: NCT01307020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, oral film-coated table, once
Study: NCT01307020
Drug: Dexketoprofen Trometamol + Tramadol Hydrochloride
Normalized name: dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: DKP-TRIS low dose - TRAM.HCl low dose, oral film-coated table, once
Study: NCT01307020
Drug: Dexketoprofen Trometamol + Tramadol Hydrochloride
Normalized name: dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: DKP-TRIS low dose - TRAM.HCl high dose, oral film-coated table, once
Study: NCT01307020
Drug: Dexketoprofen Trometamol + Tramadol Hydrochloride
Normalized name: dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: DKP-TRIS high dose - TRAM.HCl low dose, oral film-coated tablet, once
Study: NCT01307020
Drug: Dexketoprofen Trometamol + Tramadol Hydrochloride
Normalized name: dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: DKP-TRIS high dose - TRAM.HCl high dose, oral film-coated tablet, once
Study: NCT03343418
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Patients randomized to the control group will receive the infusion of 100 milliliters (mL) 0.9% saline (SF0,9%). After 0.9% saline infusion, bleeding treatment will follow the predefined standardized treatment regimen.
Study: NCT03911843
Drug: omega-3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation with Ω-3, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at a dose of 50-60 mg/kg/day for 12 months, currently underway or completed after 12 months of omega-3 administration, in 22/64 T1D children
Study: NCT02975583
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet daily
Study: NCT00604214
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride, intravenous, 96 hours
Study: NCT00327652
Drug: CRS-100
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Live-attenuated Listeria monocytogenes
Study: NCT00402207
Drug: extrafine HFA-beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02630004
Drug: Melatonin oral gel 3%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02630004
Drug: Placebo oral gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00739622
Drug: TMC278
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01531062
Drug: Nigella sative
Normalized name: Nigella sativa seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa seed extracts, 300 mg capsule bid, for 56 days
Study: NCT00399919
Drug: PLC
Normalized name: Drive Cane Tip Rplc 3/4 Blk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 grams/day for six months
Study: NCT01066676
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg, powder for oral suspension, daily dose 1600mg
Study: NCT03120520
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00817479
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo saline
Study: NCT01216371
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one-year Treatment, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break,
Study: NCT02829944
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02829944
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03798899
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03997968
Drug: CYT-0851 in combination with capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part E: Daily oral doses of CYT-0851 for 21 days in combination with capecitabine
Study: NCT01138943
Drug: Synthodont
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml, tree times/day for 07 days~Arm: Chlorhexidine alcohol-base mouthrinse
Study: NCT02345408
Drug: CCX872-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets (oral administration)
Study: NCT02328547
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules prepared by OpenBiome, Medford, MA
Study: NCT00441207
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delivered via IV Infusion.
Study: NCT04302025
Drug: SBRT
Normalized name: Stereotactic Body Radiation Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive SBRT given concurrently starting with the first dose of atezolizumab
Study: NCT01472315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills were taken in same way as active comparator
Study: NCT01925131
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00900887
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ophthalmic presentation 5 mg/ml dosage one drop (0.25 mg) in the treated eye 3 times a day during one week
Study: NCT00900887
Drug: Nepafenac
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topic presentation 1 mg/ml dosage one drop (0.05 mg) in the treated eye 3 times a day during one week